Alumis Inc. Common Stock (ALMS)
4.31
-0.40 (-8.49%)
At close: Apr 24, 2025, 3:59 PM
4.42
2.52%
After-hours: Apr 24, 2025, 07:29 PM EDT
-8.49% (1D)
| Bid | 4.33 |
| Market Cap | 234.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -294.23M |
| EPS (ttm) | -10.38 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -1.38 |
| Analyst | Buy |
| Ask | 5 |
| Volume | 487,255 |
| Avg. Volume (20D) | 684,075 |
| Open | 4.88 |
| Previous Close | 4.71 |
| Day's Range | 4.28 - 4.92 |
| 52-Week Range | 3.18 - 13.53 |
| Beta | -2.49 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 22, 2021
Employees 168
Stock Exchange NASDAQ
Ticker Symbol ALMS
Website https://www.alumis.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ALMS stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 642.46% from the latest price.
Stock Forecasts1 month ago
+5.82%
Alumis shares are trading higher after the company...
Unlock content with
Pro Subscription
1 month ago
-18.31%
Alumis shares are trading lower after the company reported a year-over-year decline in FY24 net income results. Also, HC Wainwright & Co. cut its price target on the stock from $19 to $15.
